Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Akari Therapeutics

Request full access

Developing bi-functional antibody drug conjugates for cancer

Walton-on-Thames, United KingdomFounded 2005Biotech & Life Sciences

About Akari Therapeutics

Akari Therapeutics plc is a biotechnology company that has transitioned its focus to oncology, specifically developing next-generation bi-functional antibody-drug conjugates (ADCs) for cancer treatment. This strategic shift followed a merger with Peak Bio, Inc., which was completed in November 2024. The merger expanded Akari's pipeline to include an innovative ADC discovery platform, novel payloads, and linker technologies.

The company was originally founded as Celsus Therapeutics in 2004 and focused on autoimmune and inflammatory diseases. A key figure in its history is Dr. Ray Prudo, who founded Volution Immuno Pharmaceuticals in 2008 and joined Akari in September 2015 when Volution merged with Celsus. Over the years, the company has undergone several leadership changes. In March 2022, Rachelle Jacques was appointed President and CEO, succeeding Clive Richardson. Jacques stepped down in May 2024, and Samir Patel, a board member since December 2023, took over as interim CEO. Following the Peak Bio merger, Dr. Hoyoung Huh, the founder and Chairman of Peak Bio, became the Chairman of Akari's board. In April 2025, Abizer Gaslightwala, a seasoned biotechnology executive with over 25 years of experience, was appointed the new President and CEO.

Akari's lead ADC candidate is AKTX-101, which targets the TROP2 receptor found on various solid tumors. It delivers a proprietary, first-in-class payload called PH1, a spliceosome modulator designed to disrupt RNA splicing in cancer cells. This mechanism aims to induce tumor-specific cell death and generate an immune response, potentially overcoming limitations of existing ADCs like off-target toxicity and resistance. Before its pivot to oncology, Akari's lead asset was nomacopan, a bispecific inhibitor of complement C5 and leukotriene B4 (LTB4) for autoimmune and inflammatory diseases, which had reached Phase 3 trials for conditions like pediatric HSCT-TMA. The company is also developing a long-acting version, PAS-nomacopan, for geographic atrophy (GA).

As a publicly traded company on the Nasdaq (AKTX), Akari's business model is centered on the research and development of its therapeutic candidates. Its revenue generation will depend on the successful clinical development, regulatory approval, and subsequent commercialization or partnership of its pipeline assets. The company has secured financing through private placements and has an equity line of credit to fund its operations and development milestones.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2013

Akari Therapeutics in the Walton-on-Thames ecosystem

Live from Dealroom

The Akari Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later7 investors entered at this stage

Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States75%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Akari Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Akari Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.